Annovis Bio Inc. (NYSE: ANVS), a Phase 3 clinical-stage biotechnology company specializing in neurodegenerative diseases, has announced it will host a corporate update webinar on September 2, 2026, at 4 p.m. EDT. The webinar, led by Founder, President and CEO Maria Maccecchini, Ph.D., will provide an overview of recent progress, ongoing clinical programs, and upcoming milestones. This event is significant as it comes at a critical juncture for the company, with its pivotal Phase 3 Alzheimer’s disease (AD) trial fully enrolled and top-line data expected in 2027.
The announcement underscores the company’s commitment to advancing its lead candidate, buntanetap, an investigational oral therapy designed to inhibit the translation of multiple neurotoxic proteins implicated in neurodegeneration, including amyloid beta, tau, alpha-synuclein, and TDP-43. By targeting these underlying causes, Annovis aims to halt disease progression and improve cognitive and motor functions in patients with AD and Parkinson’s disease (PD).
During the webinar, Maccecchini will discuss the company’s plans to initiate an AD open-label study in October 2026, which will generate long-term safety data. This study is part of Annovis’ broader strategy to build a robust clinical profile for buntanetap. Additionally, the company’s PD open-label study is already underway, and discussions are ongoing regarding the initiation of a Parkinson’s disease dementia program. These efforts highlight Annovis’ dedication to addressing the full spectrum of neurodegenerative conditions.
The corporate update comes at a time of heightened interest in Alzheimer’s and Parkinson’s treatments, as the global burden of these diseases continues to rise. Annovis’ approach, which focuses on multiple neurotoxic proteins simultaneously, differentiates it from other therapies that target single pathways. If successful, buntanetap could offer a novel treatment option for millions of patients worldwide.
Investors and stakeholders will have the opportunity to participate in a live question-and-answer session following the presentation, providing clarity on the company’s strategic direction. The webinar is expected to shed light on regulatory submission timelines and the potential path to commercialization for buntanetap.
Annovis Bio, headquartered in Malvern, Pennsylvania, is dedicated to developing treatments that address the root causes of neurodegeneration. With its Phase 3 AD trial fully enrolled and multiple studies underway, the company is poised to reach significant milestones in the coming years. The webinar will serve as a platform to communicate these developments and set expectations for the future.
For more information about the webinar and to access the full press release, visit https://ibn.fm/mls3F. To stay updated on the latest news from Annovis Bio, visit the company’s newsroom at https://ibn.fm/ANVS.
